Novonesis AS

Director's Dealing • Feb 27, 2025

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B.

The Executive Leadership Team members eligible for the Novozymes A/S 2022-2024 incentive program has on February 26, 2025, received the allocated shares. An overview of the number and value of shares allotted is provided on the following pages.

February 27, 2025 Company announcement No. 04

Contact information
Investor Relations
Tobias Bjorklund	+45 3077 8682	tobb@novonesis.com
Anders Enevoldsen	+45 5350 1453	adev@novonesis.com
Katrine Spedtsberg Poulsen		kats@novonesis.com

About Novonesis

Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

Novozymes A/S, part of Novonesis Group Krogshoejvej 36 2880 Bagsvaerd Denmark

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Ester Baiget
2.	Reason forthe notification
a)	Position/status	CEO and president
b)	Initial notification/ Amendment	Initial notification
3.	auction monitor	Details of the issuer, emission allowance market participant, auction platform, auctioneer or
a)	Name	Novozymes A/S
b)	LEI	529900T6WNZXD2R3JW38
4.		Details of the transaction(s): section to be repeated for(i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description ofthe financial instrument, type of instrument	B-Shares
	Identification code	DK0060336014
b)	Nature of the transaction	Shares received as part of incentive program
c)	Price(s) and volume(s)	Price(s) DKK 428.1	Volume(s) 12,120 shares
d)	Aggregated information - Aggregated volume - Price	Number of shares: 12,120 Average price, DKK: 428.1 Transaction value, DKK: 5,188,572
e)	Date of transaction	February 26, 2025
f)	Place of the transaction	Outside a trading venue

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Amy Louise Byrick
2.	Reason forthe notification
a)	Position/status	Executive Vice President, Human Health Biosolutions
b)	Initial notification/ Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Novozymes A/S
b)	LEI	529900T6WNZXD2R3JW38
4.	Details of the transaction(s): section to be repeated for(i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description ofthe financial instrument, type of instrument	B-Shares
	Identification code	DK0060336014
b)	Nature of the transaction	Shares received as part of incentive program
c)	Price(s) and volume(s)	Price(s) DKK 428.1	Volume(s) 4,191 shares
d)	Aggregated information - Aggregated volume - Price	Number of shares: 4,191 Average price, DKK: 428.1 Transaction value, DKK: 1,794,167.10
e)	Date of transaction	February 26, 2025
f)	Place of the transaction	Outside a trading venue

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Anders Lund
2.	Reason forthe notification
a)	Position/status		Executive Vice President, Chief Operating Officer
b)	Initial notification/ Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Novozymes A/S
b)	LEI	529900T6WNZXD2R3JW38
4.		Details of the transaction(s): section to be repeated for(i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description ofthe financial instrument, type of instrument	B-Shares
	Identification code	DK0060336014
b)	Nature of the transaction	Shares received as part of incentive program
c)	Price(s) and volume(s)	Price(s) DKK 428.1	Volume(s) 9,002 shares
d)	Aggregated information - Aggregated volume - Price	Number of shares: 9,002 Average price, DKK: 428.1 Transaction value, DKK: 3,853,756.20
e)	Date of transaction	February 26, 2025
f)	Place of the transaction	Outside a trading venue

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Claus Crone Fuglsang
2.	Reason forthe notification
a)	Position/status		Executive Vice President, Chief Scientific Officer
b)	Initial notification/ Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Novozymes A/S
b)	LEI	529900T6WNZXD2R3JW38
4.		Details of the transaction(s): section to be repeated for(i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description ofthe financial instrument, type of instrument	B-Shares
	Identification code	DK0060336014
b)	Nature of the transaction	Shares received as part of incentive program
c)	Price(s) and volume(s)	Price(s) DKK 428.1	Volume(s) 6,752 shares
d)	Aggregated information - Aggregated volume - Price	Number of shares: 6,752 Average price, DKK: 428.1 Transaction value, DKK: 2,890,531.20
e)	Date of transaction	February 26, 2025
f)	Place of the transaction	Outside a trading venue

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Morten Enggaard Rasmussen
2.	Reason forthe notification
a)	Position/status	Executive Vice President, People & Stakeholder Relations
b)	Initial notification/ Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Novozymes A/S
b)	LEI	529900T6WNZXD2R3JW38
4.	Details of the transaction(s): section to be repeated for(i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description ofthe financial instrument, type of instrument	B-Shares
	Identification code	DK0060336014
b)	Nature of the transaction	Shares received as part of incentive program
c)	Price(s) and volume(s)	Price(s) DKK 428.1	Volume(s) 2,993 shares
d)	Aggregated information - Aggregated volume - Price	Number of shares: 2,993 Average price, DKK: 428.1 Transaction value, DKK: 1,281,303.30
e)	Date of transaction	February 26, 2025
f)	Place of the transaction	Outside a trading venue

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Tina Sejersgård Fanø
2.	Reason forthe notification
a)	Position/status	Executive Vice President, Planetary Health Biosolutions
b)	Initial notification/ Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Novozymes A/S
b)	LEI	529900T6WNZXD2R3JW38
4.		Details of the transaction(s): section to be repeated for(i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description ofthe financial instrument, type of instrument	B-Shares
	Identification code	DK0060336014
b)	Nature of the transaction	Shares received as part of incentive program
c)	Price(s) and volume(s)	Price(s) DKK 428.1	Volume(s) 9,002 shares
d)	Aggregated information - Aggregated volume - Price	Number of shares: 9,002 Average price, DKK: 428.1 Transaction value, DKK: 3,853,756.20
e)	Date of transaction	February 26, 2025
f)	Place of the transaction	Outside a trading venue